DXCM vs REPL · P/E 63, rev $4.03B vs $825.7M cap
DexCom Inc (DXCM) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported DXCM revenue for 2024-12-31 was $4.03B. Net income was $576.2M. Revenue was up 11.3% from 2023-12-31 to 2024-12-31. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
REPL does not have a complete income-statement cache yet.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. REPL currently screens at market cap $825.7M.
Not investment advice. Open the DXCM and REPL stock pages for the full models.
Not investment advice.